Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Telmisartan

K J McClellan1, A Markham

  • 1Adis International Limited, Auckland, New Zealand. demail@adis.co.nz

Drugs
|January 8, 1999
PubMed
Summary
This summary is machine-generated.

Telmisartan effectively lowers blood pressure in hypertensive patients, demonstrating comparable or superior efficacy to other common antihypertensives. This angiotensin II receptor blocker shows a favorable safety profile, similar to placebo.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Large-grain scintillator screens for proton radiography.

The Review of scientific instruments·2024
Same author

Kondo quasiparticle dynamics observed by resonant inelastic x-ray scattering.

Nature communications·2022
Same author

Cabotegravir Plus Rilpivirine: First Approval.

Drugs·2020
Same author

Physics-informed machine learning for inorganic scintillator discovery.

The Journal of chemical physics·2018
Same author

Benralizumab: First Global Approval.

Drugs·2018
Same author

Pergolide : A Review of its Pharmacology and Therapeutic Use in Parkinson's Disease.

CNS drugs·2016
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Hypertension Research

Background:

  • Telmisartan is a selective, nonpeptide angiotensin II receptor antagonist.
  • It inhibits the AT1 receptor subtype without impacting other cardiovascular regulatory systems.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of telmisartan in managing hypertension.
  • To compare telmisartan's blood pressure-lowering effects against placebo and other antihypertensive agents.

Main Methods:

  • Dose-dependent reduction in blood pressure observed in animal models of hypertension.
  • Clinical trials involving patients with mild-to-moderate and severe hypertension.
  • Ambulatory blood pressure monitoring used in specific comparative studies.

Related Experiment Videos

Main Results:

  • Telmisartan significantly reduced systolic and diastolic blood pressure compared to placebo.
  • Efficacy was comparable or superior to atenolol, lisinopril, enalapril, losartan potassium, and amlodipine.
  • Telmisartan demonstrated a tolerability profile similar to placebo.

Conclusions:

  • Telmisartan is an effective antihypertensive agent for various degrees of hypertension.
  • Its efficacy and tolerability support its use as a therapeutic option.
  • Telmisartan provides sustained blood pressure control over the dosing interval.